[1] Vanharanta S, Buchta M, McWhinneyS R, et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma[J]. Am J Hum Genet, 2004, 74(1): 153-159.
[2] Moch H, Cubilla A I, Humphrey P A,et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, testicular tumours[J].Eur Urol, 2016, 70(1): 93-105.
[3] Burnichon N,Brière J J,Libé R,et al.SDHA is a tumor suppressor gene causing paraganglioma[J].Hum Mol Genet,2010,19(15):3011-3020.
[4] Zhao T,Mu X,You Q.Succinate: an initiator in tumorigenesis and progression[J].Oncotarget,2017,8(32): 53819-53828.
[5] Rizza S,Montagna C,Cardaci S,et al.S-nitrosylation of the mitochondrial chaperone TRAP1 sensitizes hepatocellular carcinoma cells to inhibitors of succinate dehydrogenase[J].Cancer Res,2016,76(14):4170-4182.
[6] Ishii T,Miyazawa M,Onouchi H,et al.Model animals for the study of oxidative stress from complex II[J].Biochim Biophys Acta,2013,1827(5):588-597.
[7] Mu X,Zhao T,Xu C,et al.Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation[J].Oncotarget,2017,8(8):13174-13185.
[8] Astuti D, Latif F, Dallol A, et al. Gene mutation in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma[J]. Am J Hum Genet, 2001,69(1):49-54.
[9] Menendze J A, Alarcon T, Joven J. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites[J]. Cell Cycle,2014, 13(5):699-709.
[10] Williamson S R, Eble J N, Amin M B, et al. Succinate dehydrogenase-deficient renal cell carcinoma: detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma[J]. Mod Pathol, 2015,28(1):80-94.
[11] Gill A J, Ondrej H, Thomas P, et al. Succinate dehydrogenase(SDH)-deficient renal carcinoma : a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients[J]. Am J Surg Pathol, 2014,38(12):1588-1602.
[12] 武 静,成元华,张亚娟,等.琥珀酸脱氢酶缺陷型肾细胞癌的临床病理特征[J].实用医学杂志,2019,35(14):2304-2307.
[13] 刘浩然,叶章群.肾癌基础研究新进展[J].现代泌尿生殖肿瘤杂志,2017, 9(5):257-261.
[14] Kuroda N, Yorita K, Nagasaki M, et al. Review of succinate dehydrogenase-deficient renal cell carcinoma with focus on clinical and pathobiological aspects[J]. Pol J Pathol,2016, 67(1):3-7.
[15] 田 佳,莫文法,陆文恺,等.琥珀酸脱氢酶B缺陷相关的肾细胞癌转移至颈部一例[J].中华病理学杂志, 2018,47(8): 641-642.
[16] Sun A,LiuZ S, Wang T,et al. Succinate dehydrogenase-deficient renal cell carcinoma: a case report and review of the literature[J].Asian J Surg,2021,44(4):692-693.
[17] Ozluk Y, Taheri D, Matoso A, et al. Renal carcinoma associated with a noval succinate dehydrogenase a mutation: a case report and review of literature of a rare subtype of renal carcinoma[J]. Hum Pathol,2015, 46(12):1951-1955.
[18] Yakirevich E, Ali S M, Mega A, et al. A novel SDHA-deficient renal cell carcinoma revealed by comprehensive genomic profiling[J]. Am J Surg Pathol, 2015, 39(6):858-863.
[19] Ricketts C J,Shuch B,Vocke C D,et al.Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer[J].J Urol,2012,188(6):2063-2071.
[20] 肖 芹,陈 静,刘 丹,等.琥珀酸脱氢酶缺陷型肾细胞癌的临床病理分析[J].中华病理学杂志,2019,48(10):796-798.
[21] 赵 媛,陈 红,金木兰. 琥珀酸脱氢酶缺陷型肾癌1例并文献复习[J]. 临床与实验病理学杂志,2019, 35(12):1472-1474.
[22] Aghamir S,Heshmat R,Ebrahimi M,et al.The impact of succinate dehydrogenase gene (SDH) mutations in renal cell carcinoma (RCC): a systematic review[J].Onco Targets Ther,2019, 9(12):7929-7940.
[23] Paik J Y, Toon C W, Benn D E, et al. Renal carcinoma associated with B mutation: a new and unique subtype of renal carcinoma[J]. J Clin Oncol, 2014,32(6):e10-13.
[24] McEvoy C R, Koe L, Choong D Y, et al. SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response[J]. NPJ Precis Oncol, 2018,2(1):1-5.